NEWS & MEDIA

NEOVACS REPORTS FIRST POSITIVE IMMUNOGENICITY RESULTS FOR IFNα KINOID IN MODEL OF TYPE 1 DIABETES

Paris and Boston, January 25, 2017 – Neovacs (Alternext Paris: ALNEV),

 

 

 

a leader in active immunotherapies for the treatment of autoimmune diseases, today announced the recommendation of its Scientific Advisory Board to extend the development of IFN Kinoid to a new indication, Type 1 Diabetes, with the objectives of obtaining preclinical proof of concept in 2017 and initiating clinical development for this program in the first half of 2018. IFN Kinoid is also currently in Phase IIb testing for treatment of Lupus and recently received U.S. FDA Fast Track designation in this indication.

download the pdf